← Eichor
Condition: Gvhd Graft Versus Host Disease Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Gvhd Graft Versus Host Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hemato
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07235501Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute
Phase 2 · 11 location(s) · ReAlta Life Sciences, Inc. · NCT06343792Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase 4 · 2 location(s) · Hospices Civils de Lyon · NCT05743400Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
Phase 2 · 3 location(s) · Fred Hutchinson Cancer Center · NCT07011810Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens
Phase 2/Phase 3 · 56 location(s) · University Hospital, Angers · NCT02416388oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort
Phase N/A · 1 location(s) · The University of Hong Kong · NCT05170347A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07594587Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Foll
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05470491Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyc
Phase 1 · 2 location(s) · University of Kansas Medical Center · NCT03533816A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Phase 2 · 121 location(s) · Syndax Pharmaceuticals · NCT04710576BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
Phase 2 · 1 location(s) · BioPhoenix Co., Ltd. · NCT07246031A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD
NA · 1 location(s) · Anhui Provincial Hospital · NCT06321198A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di
Phase 2 · 41 location(s) · Incyte Corporation · NCT07124078Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Vir
Phase 4 · 1 location(s) · Beijing Children's Hospital · NCT07029958Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )
Phase 2 · 1 location(s) · Daihong Liu · NCT07340723A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT
Phase 2 · 1 location(s) · WeiShi · NCT07606703The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft Vs. Host Disease (GVHD) Patients
Phase N/A · 1 location(s) · Indiana University · NCT04700657Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06996119Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Phase 2/Phase 3 · 1 location(s) · Hospital Israelita Albert Einstein · NCT03818334Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07366801Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
Phase 1 · 1 location(s) · University of Wisconsin, Madison · NCT06392711Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT
Phase 3 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07689630Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
Phase 2 · 15 location(s) · Boston Children's Hospital · NCT04380740The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofet
Phase 1/Phase 2 · 2 location(s) · National Cancer Institute (NCI) · NCT05436418Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
Phase 2 · 3 location(s) · University Hospital, Basel, Switzerland · NCT03805477Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
Phase 1/Phase 2 · 1 location(s) · Northwell Health · NCT05289167MAGIC Ruxolitinib for aGVHD
Phase 2 · 14 location(s) · John Levine · NCT06936566Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT07238712Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Yo
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT06756152
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.